Targeting this loop through the combined use of demethylating agents and TGF-β pathway inhibitors therefore represents a promising therapeutic avenue to disrupt the epigenetic reinforcement of the ovarian cancer microenvironment [88]. The gene discussed is TGFB1; the disease is ovarian carcinoma.